We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Adoptive Transfer of HBsAg-specific Splenocytes from Balb/c Congenic Donors into HBsAg Transgenic Mice is not associated to Histopathological Damage.
- Authors
Lobaina, Yadira; García, Daymir; Blanco, Aracelys; Hernéndez, Dunia; Trujillo, Heidy; Freyre, Freya; Merino, Nelson; Suárez, Jose; Ancízar, Julio; Martínez, Leticia; Aguilar, Julio Cesar
- Abstract
Background: Hepatitis B virus (HBV) infections remain as a major health problem. It has been estimated that about 370 million people are chronically infected worldwide. Chronic infection also increases the risk of liver diseases such as cirrhosis and hepatocellular carcinoma. Current antiviral therapies fail to control viral replication in the long term. Viral persistence has been associated with a defect in the development of HBV-specific cellular immunity. The limitations of the current available therapies underline the need for alternative therapies. The development of a HBV therapeutic vaccine still remains as a feasible option of treatment despite several drawbacks. Recently, approaches like adoptive T-cell therapy have been evaluated. Materials and methods: The adoptive transfer was done intraperitoneally using Balb/c mice as donors and HBsAgtransgenic mice as receptors. The HBsAg concentration, specific IgG response and biochemical parameters was evaluated in transgenic mice sera by ELISA. The histopathological analysis of the main organs was carried out. Results and discussion: In the present work we demonstrated that the adoptive transfer of HBV-specific cellular immunity did no cause histopathological damage. The potent immune response transferred was developed in non-Tg Balb/c mice after multiple simultaneous intranasal and subcutaneous immunizations with NASVAC, a novel HBV therapeutic vaccine candidate. The results indicated that the transference of immunity is safe and also capable of transiently reducing the HBsAg concentration in the sera of transgenic mice. These data support the safety of the therapeutic vaccination using NASVAC and also are in line with the usefulness of the T-cell therapy for chronic hepatitis B.
- Subjects
HEPATITIS B virus; TRANSGENIC mice; LIVER diseases; CIRRHOSIS of the liver; LIVER cancer; T cells; DISEASE risk factors; THERAPEUTICS
- Publication
Euroasian Journal of Hepato-Gastroenterology, 2013, Vol 3, Issue 2, p97
- ISSN
2231-5047
- Publication type
Article
- DOI
10.5005/jp-journals-10018-1074